tradingkey.logo
搜索

AIM ImmunoTech Inc

AIM
添加自选
0.251USD
-0.007-2.56%
交易中 美东报价延迟15分钟
772.54K总市值
亏损市盈率 TTM

AIM ImmunoTech Inc

0.251
-0.007-2.56%

关于 AIM ImmunoTech Inc 公司

AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.

AIM ImmunoTech Inc简介

公司代码AIM
公司名称AIM ImmunoTech Inc
上市日期Jul 12, 1996
CEOEquels (Thomas K)
员工数量21
证券类型Ordinary Share
年结日Jul 12
公司地址2117 Sw Highway 484
城市OCALA
上市交易所NASDAQ OMX – NASDAQ Basic Amex
国家United States of America
邮编32801
电话13524487797
网址https://aimimmuno.com/
公司代码AIM
上市日期Jul 12, 1996
CEOEquels (Thomas K)

AIM ImmunoTech Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
63.92K
+39.13%
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
28.44K
+97.74%
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
+0.04%
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
-0.03%
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter W. Rodino, III
Mr. Peter W. Rodino, III
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
--
--
Ms. Jenene Thomas
Ms. Jenene Thomas
Investor Relations
Investor Relations
--
--
Mr. Ted D. Kellner
Mr. Ted D. Kellner
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
63.92K
+39.13%
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
28.44K
+97.74%
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
+0.04%
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
-0.03%
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter W. Rodino, III
Mr. Peter W. Rodino, III
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
--
--

收入明细

由于公司未披露,未能获取相关数据
由于公司未披露,未能获取相关数据
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 5月14日 周四
更新时间: 5月14日 周四
持股股东
股东类型
持股股东
持股股东
占比
DRW Securities, LLC
0.85%
Equels (Thomas K)
0.78%
Kellner (Theodore D)
0.46%
Chemerow (David I)
0.35%
Jane Street Capital, L.L.C.
0.25%
其他
97.31%
持股股东
持股股东
占比
DRW Securities, LLC
0.85%
Equels (Thomas K)
0.78%
Kellner (Theodore D)
0.46%
Chemerow (David I)
0.35%
Jane Street Capital, L.L.C.
0.25%
其他
97.31%
股东类型
持股股东
占比
Individual Investor
2.00%
Investment Advisor
1.08%
Investment Advisor/Hedge Fund
0.21%
其他
96.70%

机构持股

更新时间: 4月1日 周三
更新时间: 4月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2026Q1
57
105.74K
1.30%
-74.29K
2025Q4
56
107.25K
2.64%
--
2025Q3
59
107.25K
2.79%
+95.13K
2025Q2
58
12.12K
12.55%
-36.20K
2025Q1
67
48.31K
13.00%
-45.65K
2024Q4
64
46.48K
14.87%
-43.65K
2024Q3
61
90.13K
15.18%
+5.69K
2024Q2
61
84.44K
8.12%
+43.50K
2024Q1
64
40.95K
9.51%
-6.49K
2023Q4
65
41.55K
9.71%
-1.72K
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
DRW Securities, LLC
69.61K
0.85%
+26.28K
+60.65%
Dec 31, 2025
Equels (Thomas K)
63.92K
0.78%
+25.01K
+64.29%
Mar 25, 2026
Kellner (Theodore D)
37.24K
0.46%
-2.00
-0.01%
Mar 25, 2026
Chemerow (David I)
28.44K
0.35%
+27.80K
+4330.06%
Mar 25, 2026
Geode Capital Management, L.L.C.
17.39K
0.21%
+1.19K
+7.35%
Dec 31, 2025
Deutsch (Todd A)
17.18K
0.21%
--
--
Dec 19, 2024
Mitchell (William M)
5.22K
0.06%
+2.00
+0.04%
Mar 25, 2026
Rodino (Peter W III)
4.02K
0.05%
+3.00
+0.07%
Mar 25, 2026
查看更多

持股ETF

更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
占比0%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
除权除息日
类型
比率
Mar 03, 2025
Merger
100→1
公告日期
除权除息日
类型
比率
Mar 03, 2025
Merger
100→1
KeyAI